Propanc Biopharma, Inc.

Stage 4 · Declining · week 56

As of Oct 22, 2026, Propanc Biopharma is in Stage 4, the downtrend phase, now in week 56 (since Sep 17, 2025). It closed at $0.27, 99.3% below its 52-week high and below its 200-day average, which is falling.

$0.27

-12.32% today

$2.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PPCB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 76w

S4 57w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 76w → S1 6w → S2 6w → S3 5w → S4 8w → S1 1w → S2 5w → S3 2w → S4 57w current

Total tracked: 166 weeks across 9 stage runs.

PPCB among Biotechnology543rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…543	PPCBPropanc Biopharma, Inc.	Stage 4 · wk 56	3	−56.4%

vs 52W High

-99.3%

$0.27 lo$38.00 hi

99.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 56

1w13w26w

Week 56, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-89.8%

200 DMA: $2.68 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.09x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-56.4%

-80.0%

-90.6%

YTD

-98.1%

-99.3%

Scan Membership

Breakout Watch

Latest: 2025-03-14

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 56 · Vol 0.09x

2026-10-21S4

Wk 56 · Vol 0.02x

2026-10-20S4

Wk 55 · Vol 0.05x

2026-10-19S4

Wk 55 · Vol 0.10x

2026-10-16S4

Wk 55 · Vol 0.90x

2026-10-15S4

Wk 55 · Vol 0.07x

2026-10-14S4

Wk 55 · Vol 0.36x

2026-10-13S4

Wk 54 · Vol 0.15x

2026-10-12S4

Wk 54 · Vol 0.09x

2026-10-09S4

Wk 54 · Vol 0.08x

2026-10-08S4

Wk 54 · Vol 0.09x

2026-10-07S4

Wk 54 · Vol 0.39x

Moving averages & range

50 DMA

$0.78

200 DMA

$2.68

52W High

$38.00

52W Low

$0.27

5D Low

$0.27

Resistance levels (recent highs)

20d High

$0.63

60d High

$2.23

120d High

$2.58

250d High

$38.00

Next resistance

+130.0%

to 20d High

ROE

-161.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.1

Propanc Biopharma: quick answers

What stage is Propanc Biopharma in?

As of Oct 22, 2026, Propanc Biopharma (PPCB) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 17, 2025 and is in week 56. What the four stages mean

Is Propanc Biopharma in an uptrend?

No. Propanc Biopharma is in a Stage 4 downtrend. It trades 89.8% below its 200-day average, which is falling.

How far is Propanc Biopharma from its 52-week high?

Propanc Biopharma closed at $0.27 on Oct 22, 2026, 99.3% below its 52-week high of $38.00. Its 52-week low is $0.27.

How has Propanc Biopharma performed over the past year?

As of Oct 22, 2026, Propanc Biopharma is down 99.3% over the past year and down 98.1% so far in 2026.

Which sector and industry is Propanc Biopharma in?

Propanc Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.